PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Negative EBIT growth while Biotechnology median is -0.09%. Seth Klarman would check if external or internal factors caused the decline.
-26.14%
Negative operating income growth while Biotechnology median is -1.59%. Seth Klarman would check if structural or cyclical issues are at play.
-26.43%
Negative net income growth while Biotechnology median is -1.72%. Seth Klarman would investigate factors dragging net income down.
-26.52%
Negative EPS growth while Biotechnology median is 2.08%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-26.52%
Negative diluted EPS growth while Biotechnology median is 1.95%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.09%
Share reduction exceeding 1.5x Biotechnology median of 0.65%. Joel Greenblatt would applaud significant buybacks if they are value-accretive.
0.09%
Diluted share reduction exceeding 1.5x Biotechnology median of 0.78%. Joel Greenblatt would see a meaningful advantage if shares are undervalued.
No Data
No Data available this quarter, please select a different quarter.
-57.07%
Negative OCF growth while Biotechnology median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-57.72%
Negative FCF growth while Biotechnology median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13659.85%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
12.78%
OCF/share CAGR of 12.78% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
32.48%
3Y OCF/share growth of 32.48% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-18544.23%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
7.55%
Net income/share CAGR of 7.55% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
44.34%
3Y net income/share CAGR of 44.34% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
1862.49%
Equity/share CAGR of 1862.49% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
309.42%
5Y equity/share CAGR of 309.42% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-81.93%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.47%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-33.19%
Negative BV/share change while Biotechnology median is -6.56%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
26.95%
R&D growth of 26.95% while Biotechnology median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
24.63%
SG&A growth of 24.63% while Biotechnology median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.